MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
Portfolio Pulse from Vandana Singh
MIRA Pharmaceuticals' stock surged after revealing that its novel oral ketamine analog, Ketamir-2, is 60% more effective than gabapentin in treating chemotherapy-induced neuropathic pain in preclinical studies. The company plans to submit an IND application by 2024 and start Phase I trials in 2025.
October 28, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' Ketamir-2 demonstrated 60% greater efficacy than gabapentin in preclinical studies for chemotherapy-induced neuropathic pain, leading to a 40.3% increase in stock price.
The significant improvement in efficacy of Ketamir-2 over an FDA-approved drug like gabapentin is a strong positive signal for MIRA Pharmaceuticals. The stock price increase of 40.3% reflects investor optimism about the potential of Ketamir-2. The company's plans to submit an IND application and start clinical trials further support the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100